一份新补充材料在一项小型研究中显示体重大幅度下降,为那些因保险限额而得不到GLP-1药物的人提供了一种替代办法。 A new supplement showed significant weight loss in a small study, offering an alternative for those denied GLP-1 drugs due to insurance limits.

许多美国人难以获得GLP-1减重药品,原因是严格的保险限额,往往需要2型糖尿病或高血压指数等条件。 Many Americans face difficulty accessing GLP-1 weight-loss medications due to strict insurance limits, often requiring conditions like Type 2 diabetes or high BMI. 专家警告说,阻止这些药物经常导致重量的恢复,主要是脂肪,代谢健康恶化。 Experts warn that stopping these drugs frequently leads to weight regain, primarily as fat, worsening metabolic health. 一种名为Motus的补充剂,由Tonum Health开发,在100名参与者进行的六个月的研究中显示出有前景的结果,平均体重减轻10.4%,主要是脂肪量减少,尽管该产品没有经过FDA审查,并且没有热量或运动要求. A supplement called Motus, developed by Tonum Health, showed promising results in a six-month study of 100 participants, with an average 10.4% weight loss and mostly fat mass reduction, though the product is not FDA-reviewed and lacks caloric or exercise requirements. 虽然改变生活方式仍然至关重要,但一些生活方式正在转向这种可持续体重管理的替代办法。 While lifestyle changes remain essential, some are turning to such alternatives for sustainable weight management.